/Investor DB

Dimension Capital — 2026 Investments

3 investments dated 2026 · listed companies and verified rows first · show all

Chai Discoverychaidiscovery.comSeries C · Jul 2026 · $400M

Chai Discovery builds a computer-aided design suite using artificial intelligence to design new molecules and drugs.

AI & Machine LearningBiotechDeep TechSan Francisco, US

Joshua Meier(Founder)inJack Dent(Founder)inJosh Meier(CEO)Jacques Boitreaud(Founder)Jacques Boutreau(Founder)Joshua Meier Jack Dent(Founder)

Co-investorsAmplify PartnersAvenir Growth CapitalavraBain Capital VenturesBattery VenturesDCVC (Data Collective)+30 more

Congruence Therapeuticscongruencetx.cominMar 2026 · $40M

Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.

AI & Machine LearningBiotechDeep Tech

Clarissa Desjardins(Founder)in

Co-investorsOrbiMedAlexandriaDIMENSIONAngelini VenturesBDC Thrive Lab for WomenBDC Thrive Venture Fund for Women+2 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Earendil Labs

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.